Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott "1st Choice Of Doctors" Infant Formula Claim "Misleading" - Judge

This article was originally published in The Tan Sheet

Executive Summary

Abbott Labs is temporarily barred from using the claim "1st choice of doctors" on advertising or labeling for its Similac or other infant brands except for Isomil in a preliminary injunction handed down March 18 by Evansville, Ind. federal court Judge David Hamilton. Mead Johnson (Enfamil) requested the injunction in a suit filed in July ("The Tan Sheet" July 27, 1998, p. 1).

You may also be interested in...



Similac "1st Choice Of Doctors" Claim Injunction Reversed

Abbott Labs plans to resume use of the "1st Choice of Doctors" claim in labeling and advertising for Similac infant formula following a Jan. 5 federal appellate ruling overturning a preliminary injunction restricting use of the statement.

Similac "1st Choice Of Doctors" Claim Injunction Reversed

Abbott Labs plans to resume use of the "1st Choice of Doctors" claim in labeling and advertising for Similac infant formula following a Jan. 5 federal appellate ruling overturning a preliminary injunction restricting use of the statement.

Similac "1st Choice Of Doctors" Claim Injunction Reversed

Abbott Labs plans to resume use of the "1st Choice of Doctors" claim in labeling and advertising for Similac infant formula following a Jan. 5 federal appellate ruling overturning a preliminary injunction restricting use of the statement.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel